Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968812 · ClinicalTrials.gov registry record · Phase 3
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,452
- Enrollment target
NCT00968812 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,452 participants.
The verdict
NCT00968812, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,452 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
Interventions
- DRUG Metformin
- DRUG Glimepiride
- DRUG Canagliflozin (JNJ-28431754)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,452 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968812
The ClinicalTrials.gov registry entry for NCT00968812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00968812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00968812 about?
NCT00968812 is a clinical study titled "CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride". The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
What is the current status of trial NCT00968812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,452 participants. The study started on 2009-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00968812?
The interventions under investigation include: Metformin (DRUG), Glimepiride (DRUG), Canagliflozin (JNJ-28431754) (DRUG).
Who is sponsoring clinical trial NCT00968812?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.